Arteris, Inc. (AIP) Stock Price & How to Invest

Arteris sells the plumbing that connects the pieces of a modern chip. Its network-on-chip (NoC) interconnect IP, sold under names like FlexNoC, Ncore, and the newer FlexGen, sits between the CPU, GPU, memory, and accelerator blocks on a system-on-chip and manages how data moves between them. Chip designers license this IP rather than build it themselves, which saves engineering time on increasingly complex designs. Arteris makes money in two layers: up-front and recurring license fees (tracked as annual contract value, or ACV) plus per-unit royalties that accrue every time a customer ships a chip containing its IP. That royalty stream is why the company reports metrics like combined ACV plus royalties (around $92.8 million exiting Q1 2026, up 39% year over year) and remaining performance obligations (about $118 million) alongside GAAP revenue.

Founded in 2003 and headquartered in Campbell, California, Arteris went public on Nasdaq in 2021 under the ticker AIP. Its IP has shipped in more than 4 billion devices, and its customer roster spans large semiconductor and technology names including AMD, NXP, and AI-chip startup Tenstorrent, across automotive, AI and machine learning, enterprise computing, and consumer markets. The AI and chiplet boom has raised demand for exactly the kind of high-bandwidth on-chip connectivity Arteris specializes in, and the 2025 launch of FlexGen (a smart, more automated NoC generator) plus the acquisition of hardware-security firm Cycuity broadened its footprint. The stock rose sharply over the trailing year, which lifted the valuation well ahead of current revenue.

Arteris is unprofitable on a GAAP basis and trades at a steep price-to-sales multiple (well above 20x) after the stock rose sharply over the past year, which leaves little room for disappointment. Royalty revenue depends on customers actually shipping chips, so it is exposed to the semiconductor cycle and to design cancellations or delays. The customer base is concentrated among a relatively small number of large chipmakers, and it competes with far larger EDA and IP vendors such as Cadence and Synopsys, plus the risk that big customers build interconnect in-house. Ongoing stock-based compensation dilutes shareholders, and a planned CFO transition in 2026 adds some management-continuity uncertainty.

5 analysts publish price targets on AIP, averaging $38.20 against a $29.88 price as of August 2026, or +27.8%. The published targets run from $35.00 to $40.00, a narrow spread, and the ratings split 4 buy, 1 hold, 0 sell. Over the last six months there have been 3 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full AIP forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Arteris, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. AI and chiplet demand tailwind. As chips get more complex and shift toward multi-die chiplet designs, the interconnect fabric Arteris licenses becomes harder to build in-house and more valuable. The most optimistic published target, $40.00, assumes this works close to its best case.

The case against. Arteris is unprofitable on a GAAP basis and trades at a steep price-to-sales multiple (well above 20x) after the stock rose sharply over the past year, which leaves little room for disappointment. The most pessimistic target, $35.00, is roughly what AIP is worth if this bites instead.

Read the full bull and bear case on AIP, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Arteris, Inc.'s investor relations page or your broker.

• Revenue (Q1 2026 quarterly): ~$22.9 million, up ~39% year over year
• ACV plus royalties (exiting Q1 2026): ~$92.8 million, up ~39%
• Full-year 2026 revenue guidance: ~$91 to $95 million, with positive free cash flow
• Net income (trailing): ~negative (net loss; not yet GAAP profitable)
• Price-to-sales ratio: ~27x
• Market cap: ~$2.0 billion (stock ~$47 per share)

Figures are approximate and tied to the asOf date, so verify live numbers before acting. AIP trades on a high price-to-sales multiple with a negative P/E because it is still unprofitable, so traditional earnings multiples do not apply. The valuation prices in continued rapid growth in contracts and royalties, which means the figures matter most as a gauge of how much optimism is already reflected in the stock.

These are the investment theses AIP naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to AIP: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get AIP exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so AIP sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where AIP fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Arteris is a small, fast-growing but still unprofitable IP-licensing business riding the AI and chiplet design wave, trading at a rich price-to-sales multiple after a large run-up, so the central question is whether royalty and contract growth can eventually catch up to the valuation.

Whether AIP is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AIP a buy or a sell?, and where the stock could go from here in the AIP stock forecast.

For income investors, whether AIP pays a dividend and how the payout looks is covered in does AIP pay a dividend? And to weigh AIP against a peer, read the full side-by-side comparisons: AIP vs AAPL and AIP vs ADBE.